While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is ...

The National Alliance on Mental Illness (NAMI) issued a response to the bill, stating that the cuts to Medicare and Medicaid ...

Traditionally, COVID vaccines have been delivered via injections. According to the Cincinnati Children’s Hospital Medical ...

This Peer Exchange® starts off with an introduction of the panel: Edward Ahn, CEO of MEDIPOST, Inc.; Rob Philo, Founder and CEO of Core Market Access Advisors; and Shana Gunderson Hua, PharmD, Vice ...

We are at an inflection point that is driving a renaissance in antibody-drug conjugate (ADC) development. As successes in the clinic have led to more U.S. Food & Drug Administration (FDA) approvals, ...

Key Takeaways Pharmaceutical innovation is thriving, but regulatory lag hinders progress. Despite breakthroughs in treatments for diseases like hepatitis C, HIV, and cystic fibrosis, outdated FDA ...

Lilly Expands Gene Editing Portfolio with Verve Therapeutics Acquisition: The $1 billion deal includes VERVE-102, a first-in-class, in vivo gene editing candidate targeting PCSK9 for atherosclerotic ...

Although a lot of data exists about using GLP-1 medications to treat diabetes, there isn’t as much data yet supporting their long-term use for obesity. What we do know is that patients appear to ...

FDA Approves Ibtrozi for ROS1+ NSCLC: Ibtrozi (taletrectinib) has been approved for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC), based on strong results ...